ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 268

Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics

Deborah Barthel1 and Gerd Horneff2, 1Paediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adalimumab, etanercept, inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA) and methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) treated with biologics. Methods: Baseline demografics, clinical characteristics and medication have been documented in the German BIKER JIA registry between 2001 and 2013. Exposure time of treatment was used to calculate IBD incidence. Published data of IBD incidence in the general pediatric population were used as reference.

Results:

3070 patients were followed in the BIKER registry with a total observation time of 8389 patient years (py). 13 events of IBD-flares in 12 patients (33% male), 8 with Crohn’s disease (CD, 67%) and 4 with ulcerative colitis (UC, 33%). were documented.

4 patients had extended oligoarthritis (eoJIA, 33%), 3 seronegative polyarthritis (RF-JIA, 25%), 3 enthesitis-related arthritis (ERA, 25%) and 2 psoriatic JIA (PsA, 17%). HLA-B27 was positive in 3 (25%) and anti-nuclear antibodies were positive in 7 IBD patients (58%).

Thus patient with IBD as adverse event more commonly had ERA, eoJIA and PsA than expected in the total BIKER cohort, but not statistitically significant. No IBD occurred in systemic JIA, RF positive or pers-oligo JIA. IBD incidence in patients with pers-oligo JIA was significantly decreased.

IBD incidence in JIA patients was 143/100,000 py and significantly higher than IBD incidence in the general pediatric population (5.2/100,000 py, p<0.001; OR 27.50 [15.54-48.67]). Mean disease duration until IBD was 7.8 ± 4.0 years (1.8-16.8).

The total exposure time was 4575PY for NSAIDs, 1981PY for corticosteroids, 195PY for sulfasalazine (SUL), 5455PY for methotrexate (MTX), 212PY for leflunomide (LEF), 3557PY for ETA and 369PY for adalimumab (ADA). Incidence of IBD was significantly higher in patients treated with etanercept (p<0.05; OR 4.53 [1.25-16.47]), leflunomide (p<0.05; OR 7.03 [1.55-31.91]) and also sulfasalazine (p<0.001; OR [12.63 (3.45-46.24]). In patients treated with methotrexate the IBD incidence decreased significantly (p<0.05; OR 0.16 [0.04-0.59]).

At admission to the registry, JIA patients later developing IBD had been treated with MTX (100%), steroids (67%), SUL (33%), azathioprine (25%), LEF (17%) and hydroxychloroquine (8%). At time of IBD diagnosis 83% were on  ETA, 33% on steroids, 25% on MTX, 25% on SUL, 17% on LEF and 1 on ADA. Thus, therapy with non-biologic agents has markedly been reduced. 

 

Results

IBD events no.

IBD-rate/1000PY

p-value

odds ratio (95% CI)

Patient cohort

JIA registry

12

1,430

<0.001

27.50 (15.54-48.67)

 

ref. population*

739

0,052

Treatment  group

NSAIDs

+

6

1.31

0.5442

0.71 (0.24-2.13)

 

–

7

1.84

Steroids

+

4

2.02

0.5437

1.44 (0.44-4.68)

 

–

9

1.40

Sulfasalazine

+

3

15.41

<0.001

12.63 (3.45-46.24)

 

–

10

1.22

MTX

+

3

0.55

0.0015

0.16 (0.04-0.59)

 

–

10

3.41

Leflunomide

+

2

9.45

0.0032

7.03 (1.55-31.91)

 

–

11

1.35

Etanercept

+

10

2.81

0.0118

4.53 (1.25-16.47)

 

–

3

0.62

Adalimumab

+

1

2.71

0.5638

1.81 (0.24-13.95)

 

–

12

1.50

* Reference population children aged <16 years (see Sawczenko et al.)

Conclusion: Incidence of IBD in JIA patients is higher than expected. Especially patients with ERA, PsA and eoJIA  are at risk. IBD seems to be associated with treatment of ETA, LEF and SUL, while MTX turned out to be protective. The impact of discontinuation of MTX, AZA and corticosteroids in patients later on developing IBD has to be discussed. Unfortunately case numbers so far are too small for further statistical analyses including linear regression models.


Disclosure:

D. Barthel,
None;

G. Horneff,

AbbVie, Pfizer, Roche,

2,

AbbVie, Novartis, Pfizer, Roche,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-bowel-disease-in-juvenile-idiopathic-arthritis-patients-upon-biologics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology